Indeed, lapatinib-resistant cells may also be primed to respond to HRG stimulation, as HER3, the cognate receptor for HRG, has been shown to be upregulated in HER2+ breast cancer models of acquired lapatinib resistance [21]. This evidence concerns the gene ERBB2 and breast cancer.